Hidradenitis suppurativa promise sends Moonlake soaring
Strong mid-stage data seem to show sonelokimab, a Merck KGaA cast-off, beating bigger rivals.
Unpartnered assets: on the shelf or hidden treasure?
A look at biopharma’s most highly valued yet unpartnered assets features Karuna, Ventyx and regular bridesmaid Ascendis.
Asco 2023 – early first-line lung cancer data mined for datopotamab gold
The search is on for signals in front-line use, where Daiichi Sankyo and Astrazeneca have already bet big with the Trop2-targeted project.
Asco 2023 – Bicara eyes head and neck niche
Impressive data in HPV-negative disease, potentially beating Keytruda, has the private group making pivotal plans.
Asco 2023 – Novartis’s adjuvant breast cancer win comes with caveats
The Natalee trial hits in all-comers, but an equivocal showing in node-negative patients raises questions about market expansion.